Homburger advised UBS Switzerland as issuer and UBS Hypotheken Schweiz as guarantor on the UBS successfull completed issuance of Covered Bonds under the program in an aggregate principal amount of EUR 1.75 bn, consisting of EUR 1
Tags :cn1
Roberto Cerratti (pictured) has joined Banca del Ceresio as Head of Investment Services Switzerland. Owned by the Foglia family, Ceresio Investors is a Swiss Group that has been active for over 100 years. Roberto Cerratti’s
From 10 to 16 June, the eighth edition of Legalcommunity Week, an event dedicated to the Italian and international legal community, will take place in Milan. This year, there will be more than twenty opportunities for
From June 10 to 16, the eighth edition of Legalcommunity Week, the event dedicated to the Italian and international legal community, will be staged in Milan. This year there will be more than twenty opportunities for
Following the completion of the acquisition of Credit Suisse Group by UBS Group on 12 June 2023, the boards of directors of UBS and Credit Suisse approved the merger between UBS and Credit Suisse (“Parent Bank Merger”).
by claudia la via Guido Wennemer, Acer’s Emea General Counsel, highlights the complex interplaybetween innovation, regulation, and legal practice in the technology sector. The technology sector is rapidly evolving and this poses significant legal
Last June, the Swiss Competition Commission (ComCo) launched an investigation into Mastercard’s domestic card-present interchange fees for its Debit and Maestro debit card products. In the meantime, Mastercard has been able to reach an
Homburger advised UBS Switzerland in its capacity as mandated lead arranger, bookrunner and agent regarding BKW ‘s new CHF 1 billion law governed revolving credit facility, which has a five-year term until 2029, with the option to
Advestra advised Wille Finance, an international Swiss-based family office focusing on private equity / venture capital, real estate and listed assets, on its anchor investment in SwissComply, a provider of outsourcing solutions for
Homburger advised ADC Therapeutics, a commercial-stage biotechnology company producing antibody drug conjugates (ADCs) for cancer patients, on its 13.4 m of common shares, and, to certain investors who so choose in lieu of common shares, pre-funded
